X-37 has closed a $14.5 million Series A financing, led by DCVC Bio and joined by Alpha Intelligence Capital and Hemi Ventures. X-37 was cofounded by AtomWise and an experienced team of pharmaceutical developers from Velocity Pharmaceutical Development. With AtomWise’s top #AI platform, we have already generated promising hits against ZAP-70 for autoimmune diseases, PIM3 and SHP2 for #cancer, and Factor XIIa #anticoagulation.


Pharmaceutical

David Collier

Kiersten Stead

Ed Schnipper

Anie Roche

Andrew Pearlman

James Larrick

X37's Leadership Team includes Andrew Pearlman and 4 others.

Leadership Team

About

Team members